New CNTY-813 Preclinical Data Demonstrate Durable Glucose Control, Immune Evasion Under Alloimmune Pressure, and Scalable Manufacturing at ADA 2026
Century Therapeutics (NASDAQ: IPSC) presented new preclinical results for CNTY-813, an iPSC-derived islet replacement engineered with Allo-Evasion™ 5.0, at ADA 2026. The company said transplanted cells maintained normoglycemia for over eight months in mice, with glucose normalization within 60 minutes in glucose tolerance tests. It also reported >50% beta-cell composition, no tumorigenesis in >140 mice, and immune evasion in humanized models without immunosuppression. Century said Phase 1 manufa
How this was made
The 30-second read
Why it matters
The article provides new, concrete preclinical efficacy (durable normoglycemia), safety (no tumorigenesis in >140 mice; no abnormal outgrowth), immune-evasion performance (in vitro and humanized mouse rejection model), and manufacturing process consistency, alongside a stated IND and first-in-human timeline.
Market read
This is a substantive preclinical and manufacturing update for Century’s lead T1D program, with explicit durability, immune-evasion, and timeline catalysts that can move biotech sentiment ahead of IND/clinical milestones.
What to watch
Key remaining uncertainties include IND-enabling study completion, scalability reproducibility at larger scale, and whether immune evasion truly eliminates immunosuppression in humans without increasing adverse immune effects.
Background
CNTY-813 is Century’s iPSC-derived islet replacement therapy engineered with Allo-Evasion™ 5.0 to aim for durable engraftment without chronic systemic immunosuppression.
Ticker impact
Century Therapeutics presented new preclinical CNTY-813 data showing >8 months durable glucose control and immune evasion without immunosuppression, plus Phase 1 manufacturing readiness and IND timing.
Near-term: supportive for sentiment into 4Q 2026 IND and 2H 2027 initial clinical data; magnitude likely limited until clinical outcomes.
The article is a conference preclinical update with specific durability, tumorigenesis absence, and process-quality claims, but no new clinical results or regulatory decision.
Market effects
Adds incremental evidence that immune-evasive, off-the-shelf iPSC islet therapies may reduce reliance on chronic immunosuppression—an important differentiator in T1D cell therapy.
No specific regional market linkage beyond biotech risk appetite.
ADA 2026 conference visibility can influence global investor sentiment toward T1D cell therapy platforms.
Counterpoint
Preclinical durability and immune-evasion signals may not translate to human efficacy or safety; tumorigenesis risk and immune escape can be more complex in patients.
Key entities
- product/programCNTY-813
iPSC-derived islet replacement therapy engineered with Allo-Evasion™ 5.0 for functional cure potential in Type 1 Diabetes.
- technologyAllo-Evasion™ 5.0
Century’s engineered immune-evasion approach intended to maintain insulin secretion under alloimmune pressure without immunosuppression.
- operationsPhase 1 manufacturing process
GMP process established for Phase 1 clinical trial supply with consistent endocrine purity and islet cell content across at-scale experiments.
- milestoneIND submission
Century expects to submit an IND in 4Q 2026; initial clinical data anticipated in 2H 2027.
